Importantly, KYNU is an enzyme of the kynurenine pathway that plays a crucial role in immune evasion in the case of TNBC.[77] Additionally, a study investigating the effect of TDO2‐AhR signaling provided more evidence of increased expression of the KYNU gene by TNBC cells.[78] Another study evaluated the clinical characteristics of KYNU expression in breast cancer patients with publicly available datasets namely TCGA and METABRIC. Here, TDO2 is linked to breast carcinoma.